MGNX

MacroGenics, Inc. (NASDAQ:MGNX) is a biopharmaceutical company founded in 2000 and headquartered in Rockville, Maryland. The company went public in October 2013 and specializes in developing and commercializing antibody-based therapeutics for cancer treatment. MacroGenics has successfully brought two FDA-approved medicines to market: MARGENZA for HER2-positive breast cancer and TZIELD for type 1 diabetes prevention. The company operates primarily through its proprietary DART (Dual-Affinity Re-Targeting) platform technology, which enables the creation of novel bispecific antibodies and antibody-drug conjugates (ADCs) designed to enhance immune system targeting of cancer cells.